Granzyme B expression correlates with poor prognosis in ovarian serous cystadenocarcinoma

Objective: The purpose of this study was to explore the expression of Granzyme B (GZMB) and its impact on the survival and prognosis of patients with ovarian serous cystadenocarcinoma (OSC) and to evaluate whether it could be used as a potential prognostic marker for OSC. Methods: The study included 43 cases of high-grade serous ovarian cancer (HGSOC) and 415 cases of OSC. Immunohistochemical analysis was performed to assess GZMB expression in cancer tissues, and the biological functions of GZMB were explored through biometric analysis. Results: In HGSOC tissues, later Federation International of Gynecology and Obstetrics (FIGO) staging was associated with lower GZMB expression (p < 0.05). Moreover, GZMB expression was significantly related to clinical stage, distant metastasis, histological grade, and survival status (p < 0.05), whereas it was not related to age (p > 0.05). GZMB was also identified as a regulator of the immune response in the tumour microenvironment. Conclusions: GZMB is closely related to the occurrence and development of OSC, participating in immune regulation; hence, it could be a potential prognostic biomarker of OSC.

Biomarker; Granzyme B; Immunity; Ovarian serous cystadenocarcinoma; Prog-nosis

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. A Cancer Journal for Clinicians. 2019; 69: 7–34.

[2] Xu Y, Xu Y, Wang C, Xia B, Mu Q, Luan S, et al. Mining TCGA database for gene expression in ovarian serous cystadenocarcinoma microenvironment. PeerJ. 2021; 9: e11375.

[3] Xie H, Wang W, Sun F, Deng K, Lu X, Liu H, et al. Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer. Scientific Reports. 2017; 7: 9896.

[4] Bian J, Li B, Kou X, Wang X, Sun X, Ming L. Clinical Applicabil-ity of Multi-Tumor Marker Protein Chips for Diagnosing Ovarian Cancer. Asian Pacific Journal of Cancer Prevention. 2014; 15: 8409–8411.

[5] Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, et al. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015; 121: 1138–1146.

[6] Mayr D, Kanitz V, Amann G, Engel J, Burges A, Löhrs U, et al. Her-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology. 2006; 48: 149–156.

[7] Turesky RJ. Mechanistic Evidence for Red Meat and Processed Meat Intake and Cancer Risk: a Follow-up on the International Agency for Research on Cancer Evaluation of 2015. CHIMIA International Journal for Chemistry. 2018; 72: 718–724.

[8] Scorilas A, Borgoño CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. Journal of Clinical Oncology. 2004; 22: 678–685.

[9] Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al. Plasma cellfree DNA in ovarian cancer. Cancer. 2010; 116: 1918–1925.

[10] Nelson G, Dowdy SC, Lasala J, Mena G, Bakkum-Gamez J, Meyer LA, et al. Enhanced recovery after surgery (ERAS®) in gynecologic oncology - Practical considerations for program development. Gynecologic Oncology. 2017; 147: 617–620.

[11] Cao J, Cai J, Huang D, Han Q, Chen Y, Yang Q, et al. MiR-335 Represents an Independent Prognostic Marker in Epithelial Ovarian Cancer. American Journal of Clinical Pathology. 2014; 141: 437–442.

[12] Qiu J, Lin Y, Ye L, Ding J, Feng W, Jin H, et al. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecologic Oncology. 2014; 134: 121–128.

[13] Li T, Liu X, Yang A, Fu W, Yin F, Zeng X. Associations of tumor suppressor t with cancer progression and prognosis. Oncology Letters. 2017; 14: 2603–2610.

[14] Adrain C, Murphy BM, Martin SJ. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lympho-cyte/natural killer (CTL/NK) protease granzyme B. The Journal of Biological Chemistry. 2005; 280: 4663–4673.

[15] Revell PA, Grossman WJ, Thomas DA, Cao X, Behl R, Ratner JA, et al. Granzyme B and the Downstream Granzymes C and/or F are Important for Cytotoxic Lymphocyte Functions. The Journal of Immunology. 2005; 174: 2124–2131.

[16] Kontani K, Sawai S, Hanaoka J, Tezuka N, Inoue S, Fujino S. Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers. European Journal of Surgical Oncology. 2001; 27: 180–186.

[17] Zhou Y, Xiong Y, Li C, Shi D. Suppression of local immune response by GrB expression in gastric cancer cells. Chinese Medical Journal. 2004; 117: 1573–1575.

[18] Andrade F. Non-cytotoxic antiviral activities of granzymes in the context of the immune antiviral state. Immunological Reviews. 2010; 235: 128–146.

[19] Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TFE, et al. Interleukin 21-Induced Granzyme B-Expressing B Cells Infiltrate Tumors and Regulate T Cells. Cancer Research. 2013; 73: 2468–2479.

[20] Hong SW, Jeong HJ, Kim SI, Moon JI, Kim YS, Park K. Granzyme B and TIA-1 Expression in Chronic and Acute on Chronic Renal Allograft Rejection. Yonsei Medical Journal. 2001; 42: 285–290.

[21] Zhao J, Zhang L, Jia L, Zhang L, Xu Y, Wang Z, et al. Secreted Antibody/Granzyme B Fusion Protein Stimulates Selective Killing of her2-overexpressing Tumor Cells. Journal of Biological Chemistry. 2004; 279: 21343–21348.

[22] Djeu J, Jiang K, Wei S. A view to a kill: signals triggering cytotoxicity. Clinical Cancer Research. 2002; 8: 636–640.

[23] Clément M, Haddad P, Ring GH, Pruna A, Sasportes M. Granzyme B- gene expression: a marker of human lymphocytes “activated” in vitro or in renal allografts. Human Immunology. 1990; 28: 159–166.

[24] Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic Oncology. 2008; 109: 370–376.

[25] Chen W, Zeng W, Li X, Xiong W, Zhang M, Huang Y, et al. MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis. Pharmacogenomics. 2016; 17: 187–197.

[26] Chen Q, Xu B, Lan L, Yang D, Yang M, Jiang J, et al. High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. Scientific Reports. 2019; 7: 8769–8778.

[27] Meng J, Li H, Zhao S, Shi H, Fu H. Expression of CXCL1 in endometrioid adenocarcinoma and its influence on proliferation and invasion of Ishikawa cells. Journal of University of Jinan. 2019; 40: 508–517.

[28] Costa-Silva J, Domingues D, Lopes FM. RNA-Seq differential ex-pression analysis: An extended review and a software tool. PLoS One. 2017; 12: e0190152.

[29] Wee Y, Liu Y, Lu J, Li X, Zhao M. Identification of novel prognosis-related genes associated with cancer using integrative network analysis. Scientific Reports. 2019; 8: 3233.

[30] Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. the Gene Ontology Consortium. Nature Genetics. 2000; 25: 25–29.

[31] Hill DP, Berardini TZ, Howe DG, Van Auken KM. Representing ontogeny through ontology: a developmental biologist’s guide to the gene ontology. Molecular Reproduction and Development. 2010; 77: 314–329.

[32] Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Research. 2017; 45: D353–D361.

[33] Talevi V, Wen J, Lalla RV, Brennan MT, Mougeot FB, Mougeot JC. Identification of single nucleotide pleomorphisms associated with periodontal disease in head and neck cancer irradiation patients by exome sequencing. Oral surgery, oral medicine, oral pathology and oral radiology. 2020; 130: 32–42.

[34] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102: 15545–15550.

[35] Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Research. 2017; 45: D362–D368.

[36] Yang L, Jing J, Sun L, Yue Y. Exploring prognostic genes in ovarian cancer stage-related coexpression network modules. Medicine. 2018; 97: e11895.

[37] Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nature Clinical Practice Oncology. 2008; 5: 588–599.